久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

日本BioWa  
BioWa 是日本領先制藥公司和最大的生物科技公司協和發酵工業株式會社 (Kyowa Hakko Kogyo Co., Ltd.) 旗下全資子公司，也是 AccretaMab(R) 平臺的全球獨家授權商。AccretaMab(R) 平臺由 POTELLIGENT(R) 技術和 COMPLEGENT(R) 技術組成，創造了一個擁有更強 ADCC 和 CDC 活性的優質抗體分子。BioWa 目前正根據授權向合作伙伴提供 POTELLIGENT(R) 和 COMPLEGENT(R) 技術，以最大限度提升這些技術的價值。BioWa 還與協和發酵工業株式會社共同專注于 ADCC/CDC 增強型單克隆抗體療法的開發，以抗擊癌癥和其它危及生命并使人體衰弱的疾病。

BioWa is committed to improving health through advancements in life science and technology. This dedication to human health has given impetus to the discovery and development of a technology that has the potential to improve the effectiveness of antibody-based treatments across many therapeutic categories.
BioWa, Inc., a New Jersey-based biotech company, was incorporated in Delaware in 2003. BioWa is committed to improving health through advancements in life science and technology. This dedication to human health has given impetus to the discovery and development of a technology that has the potential to improve the effectiveness of antibody-based treatments across many therapeutic categories.

BioWa is the exclusive worldwide licensor of Potelligent? Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies – antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). A critical function of the immune system, ADCC enhances the ability of antibodies to kill tumor cells. With BioWa’s technology, enhancement of monoclonal antibody (Mab) potency has been shown to increase up to 100 fold both in vitro and in vivo.

That’s part of the reason BioWa’s inaugural technology is called Potelligent?. The technology applies an “intelligent” approach to creating a more “potent” antibody. The rest of the reason was born out of the relationships BioWa has developed with its partners and clients. An intelligent approach goes a long way toward creating and maintaining successful alliances.

In July 2007, BioWa introduced its second technology called Complegent?, a proprietary, robust technology to enhance complement-dependent cytotoxicity (CDC) of therapeutic antibodies. Complegent? Technology may be used with Potelligent? Technology, providing AccretaMab? platform, a new class of antibodies to fight cancers and other life-threatening diseases.

As the exclusive worldwide licensor of Potelligent? and Complegent? Technologies, BioWa is committed to providing breakthrough treatments for human health through licensing the technologies to biotech and pharmaceutical companies.